RVTY

$107.31 0.00 (0.00%)

19:00 EDT RVTY Stock Quote Delayed 30 Minutes

RVTY Stock Earnings: Revvity Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings Apr 29, 2024

RVTY stock results show that Revvity beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.)

Day's Range -

52-Week Range $79.50 - $131.96

Dividend & Yield $0.28 (0.26%)

RVTY Stock Predictions, Articles, and News

From the Web

Why Revvity Stock Plunged Today

From The Motley Fool Oct 30, 2023

Revvity announced disappointing results and lowered its full-year outlook. Here's what investors need to know.

Revvity's disappointing Q3 report weighs on life sciences tool stocks (NYSE:RVTY)

From Seeking Alpha Oct 30, 2023

Revvity (RVTY) plunged to a 52-week low, dragging down other life science tool providers, after the company released a disappointing Q3 report and cut its forecast. Read more here.

Revvity expands access to base editing technology (NYSE:RVTY)

From Seeking Alpha Sep 26, 2023

Revvity unveils Pin-point base editing platform reagents, enabling researchers to implement advanced gene editing techniques in preclinical labs.

Revvity Non-GAAP EPS of $1.21 beats by $0.02, revenue of $709.27M in-line (NYSE:RVTY)

From Seeking Alpha Aug 1, 2023

Revvity press release (RVTY): Q2 Non-GAAP EPS of $1.21 beats by $0.02.Revenue of $709.27M (-20.8% Y/Y) in-line.For the full year 2023, the Company now forecasts total revenue...

Revvity declares $0.07 dividend

From Seeking Alpha Jul 21, 2023

Revvity (NYSE:RVTY) declares $0.07/share quarterly dividend, in line with previous.Forward yield 0.21%Payable Nov. 10; for shareholders of record Oct. 20; ex-div Oct.

Revvity licenses gene editing tech to AstraZeneca

From Seeking Alpha May 18, 2023

Revvity (RVTY) said it signed a non-exclusive license agreement to provide AstraZeneca (AZN) access to its gene editing technology. Read more here

ADVERTISEMENT